Home
Issues
Aim & Scope
Open Access
Indexing
Why publish with us
Contact
Editorial Board
Instructions to Authors (PDF)
Manuscript Types
Manuscript Formatting
How to submit
Preprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
Data Policies
EDITORIAL
Pirfenidone for idiopathic pulmonary fibrosis: could it be a panacea?
| 1 | Department of Thoracic Medicine, Medical School, University of Crete |
| 2 | Department of Pneumonology, Medical School, Democritus University of Thrace |
CORRESPONDING AUTHOR
Demosthenes Bouros
Dept of Pneumonology, University Hospital of Alexandroupolis Alexandroupolis, Greece, 68100
Dept of Pneumonology, University Hospital of Alexandroupolis Alexandroupolis, Greece, 68100
Pneumon 2011;24(4):352–354
KEYWORDS
REFERENCES (11)
1.
Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005; 26:693-702.
2.
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2011;183:788-824.
3.
Selman M, Pardo A, Richeldi L, Cerri S. Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs 2011;16:341-62.
4.
Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc) 2010;46:473-82. Review.
5.
Spagnolo P, Del Giovane C, Luppi F, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev 2010;(9):CD003134. Review.
6.
Noble PW, Albera C, Bradford WZ, et al; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760-9.
8.
Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
9.
Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830-6.
10.
Bouros D. Sexy and 17: Two novel pathways in immune regulation. Pneumon 2009;19:216-218.
11.
Tzouvelekis A, Bouros E, Bouros D. The immunology of pulmonary fibrosis: The role of Th1/Th2/Th17/Tregs. Pneumon 2010; 23:17-20.
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.